Mallinckrodt (MNK) Valuation Range, Estimates Cut at Wells Fargo on Methyphenidate ER Issue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Mallinckrodt (MNK), Lannett (LCI) Price Targets Lowered at Deutsche Bank After FDA Proposes to Withdraw ANDAs for Methylphenidate ER
October 17, 2016 2:01 PM EDTDeutsche Bank maintained a Buy rating on Mallinckrodt plc (NYSE: MNK) but lowered its price target to $78.00 (from $82.00). Lannett (NYSE: LCI) was maintained a Hold and its price target was lowered to $26 (from $32). Earlier the FDA proposed to withdraw approval of ANDAs for methylphenidate ER, and the update price targets reflect removing methylphenidate ER contribution. Analyst Gregg Gilbert also thinks Teva Pharma (NYSE:... More
